Chemistry:ICI-170809

From HandWiki

ICI-170809, also known as ZM-170809, is a selective serotonin 5-HT2 receptor antagonist which was under development for the treatment of major depressive disorder, arrhythmias, thrombosis, and ischemic heart disorders but was never marketed.[1][2][3][4][5] It was being developed by AstraZeneca.[1][2] The drug reached phase 2 clinical trials prior to the discontinuation of its development.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 "ICI 170809". 6 September 2000. https://adisinsight.springer.com/drugs/800001766. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on ICI-170809 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/2f57432c18de44baa8a3d5e741e6974a. 
  3. ↑ "Dimethylation of the activator ICI 169,369 results in a high-affinity partial deactivator, ICI 170,809, of the arterial 5-hydroxytryptamine2 receptor system". J Pharmacol Exp Ther 250 (2): 707–713. August 1989. doi:10.1016/S0022-3565(25)22268-6. PMID 2760851. 
  4. ↑ "5-hydroxytryptamine antagonistic effects of ICI 169,369, ICI 170,809 and methysergide in human temporal and cerebral arteries". Pharmacol Toxicol 68 (1): 8–13. January 1991. doi:10.1111/j.1600-0773.1991.tb01200.x. PMID 2008418. 
  5. ↑ "The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers". Br J Clin Pharmacol 33 (3): 281–288. March 1992. doi:10.1111/j.1365-2125.1992.tb04036.x. PMID 1576048. 





Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:ICI-170809&oldid=4033362"